Shanghai Shen Lian Biomedical Corporation (SHA:688098)
China · Delayed Price · Currency is CNY 8.81
-0.15 (-1.67%)
May 12, 2026, 3:00 PM CST
SHA:688098 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 272.12 | 288.27 | 301.93 | 300.14 | 327.87 | 357.79 |
Other Revenue | - | - | 1.48 | 1.34 | 0.72 | 0.64 |
| 272.12 | 288.27 | 303.41 | 301.49 | 328.59 | 358.43 | |
Revenue Growth (YoY) | -7.47% | -4.99% | 0.64% | -8.25% | -8.32% | 6.13% |
Cost of Revenue | 115.09 | 124.47 | 120.62 | 87.89 | 81.38 | 87.01 |
Gross Profit | 157.03 | 163.79 | 182.8 | 213.59 | 247.21 | 271.42 |
Selling, General & Admin | 125.24 | 134.29 | 155.91 | 134.72 | 128.69 | 120.97 |
Research & Development | 42.27 | 44.81 | 49.36 | 44.53 | 39.04 | 34.95 |
Other Operating Expenses | -0.62 | -1.08 | 2.76 | 3.54 | 3.43 | 3.57 |
Operating Expenses | 166.89 | 178.03 | 216.47 | 185.9 | 179.66 | 161.13 |
Operating Income | -9.86 | -14.23 | -33.67 | 27.7 | 67.56 | 110.29 |
Interest Expense | -0.4 | - | -0.02 | - | - | - |
Interest & Investment Income | - | - | 2.6 | 4.42 | 3.99 | 11.91 |
Currency Exchange Gain (Loss) | - | - | 0 | -0.02 | -0.05 | 0.01 |
Other Non Operating Income (Expenses) | -12.98 | -11.74 | -0.08 | -0.08 | -0.01 | 0.07 |
EBT Excluding Unusual Items | -23.23 | -25.98 | -31.17 | 32.02 | 71.49 | 122.29 |
Gain (Loss) on Sale of Investments | -2.02 | -0.6 | 0.88 | 2.35 | 0.35 | 1.78 |
Gain (Loss) on Sale of Assets | 0.26 | 0.26 | -0.25 | -0.4 | 0.14 | -0.6 |
Asset Writedown | -0.02 | 0.01 | -28.17 | - | -0.24 | - |
Other Unusual Items | - | - | 1.91 | 2.3 | 2.82 | 2.52 |
Pretax Income | -25.01 | -26.31 | -56.79 | 36.27 | 74.55 | 125.98 |
Income Tax Expense | -1.73 | -1.34 | -8.05 | 6.41 | 13.58 | 21.52 |
Earnings From Continuing Operations | -23.28 | -24.97 | -48.75 | 29.85 | 60.97 | 104.46 |
Minority Interest in Earnings | 4.07 | 4.48 | 4.01 | 1.67 | 0.13 | 5.74 |
Net Income | -19.21 | -20.5 | -44.74 | 31.52 | 61.1 | 110.2 |
Net Income to Common | -19.21 | -20.5 | -44.74 | 31.52 | 61.1 | 110.2 |
Net Income Growth | - | - | - | -48.42% | -44.55% | -14.91% |
Shares Outstanding (Basic) | - | 410 | 407 | 394 | 407 | 408 |
Shares Outstanding (Diluted) | - | 410 | 407 | 394 | 407 | 408 |
Shares Change (YoY) | - | 0.78% | 3.23% | -3.28% | -0.20% | -2.31% |
EPS (Basic) | - | -0.05 | -0.11 | 0.08 | 0.15 | 0.27 |
EPS (Diluted) | - | -0.05 | -0.11 | 0.08 | 0.15 | 0.27 |
EPS Growth | - | - | - | -46.67% | -44.44% | -12.90% |
Free Cash Flow | -20.4 | -12.16 | 4.45 | -126.11 | -84.04 | -98.04 |
Free Cash Flow Per Share | - | -0.03 | 0.01 | -0.32 | -0.21 | -0.24 |
Dividend Per Share | - | - | - | 0.035 | 0.080 | - |
Dividend Growth | - | - | - | -56.25% | - | - |
Gross Margin | 57.71% | 56.82% | 60.25% | 70.85% | 75.23% | 75.72% |
Operating Margin | -3.62% | -4.94% | -11.10% | 9.19% | 20.56% | 30.77% |
Profit Margin | -7.06% | -7.11% | -14.75% | 10.45% | 18.59% | 30.75% |
Free Cash Flow Margin | -7.50% | -4.22% | 1.47% | -41.83% | -25.57% | -27.35% |
EBITDA | 66.97 | 60.79 | 34.15 | 90.85 | 124.49 | 153.91 |
EBITDA Margin | 24.61% | 21.09% | 11.25% | 30.13% | 37.89% | 42.94% |
D&A For EBITDA | 76.83 | 75.03 | 67.82 | 63.15 | 56.94 | 43.62 |
EBIT | -9.86 | -14.23 | -33.67 | 27.7 | 67.56 | 110.29 |
EBIT Margin | -3.62% | -4.94% | -11.10% | 9.19% | 20.56% | 30.77% |
Effective Tax Rate | - | - | - | 17.69% | 18.21% | 17.08% |
Revenue as Reported | - | - | 303.41 | 301.49 | - | 358.43 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.